Tuesday, 28 April 2020

Cold Pain Therapy Market Overview By Trends, Industry Top Manufactures, Size, Industry Growth Analysis & Forecast Till 2023

Market Scenario:
Cold pain therapy includes the products used to reduce the pain or inflammation caused by some physical activities such as injury cause during playing or sports activity and sprain in muscle or ligament during gym. Cold therapy includes use of ice or gel packs that are kept in the freezer till needed. This therapy is largely preferred to manage the pain and swelling as it is simple to use, less expensive and gives quick results.
The market of cold pain therapy is expected to grow by increasing the demand for products to reduce the pain without medicines or by reducing the use of medicine consumption. Cold pain therapy is also use for the treatment of tennis elbow, iliotibial band syndrome, plantar fasciitis, carpel tunnel syndrome and patellofemoral pain syndrome and many more. The cold pain therapy treatment market growth was estimated USD 1.62 billion in 2017 and expected to reach USD 2.12 billion by 2023 at a CAGR of 4.6% during the forecast period. Most of the cold pain therapy are over the counter products available on online pharmacies, retailing or medical shops.  
Segmentation:
The global cold pain therapy market is segmented on the basis of product, application, therapy, and end-user. The cold pain therapy market, by product is segmented into over the counter (OTC) and prescription products. The over the counter products are sub segmented into gels, sprays, patches, cold packs, wraps, pads, and roll-ons use for the treatment of injuries.
The prescription products are sub segmented into motorized and non-motorized devices.
On the basis of application, the cold pain therapy market is segmented into musculoskeletal disorders, post-operative therapy, sports medicine, and post-trauma therapy.
On the basis of therapy, the cold pain therapy market is segmented into icepack therapy, chamber therapy and cryosurgery.
On the basis of end-user, the cold pain therapy market is segmented into hospitals and clinics, sports person, adults, and others.
Key Players:
Some of the key players in the global cold pain therapy market Medline Industries (US), Sanofi (France), Breg (US), DJO Global (US), Pfizer (US), Johnson & Johnson (US), Össur (Iceland), Performance Health (US), Beiersdorf (Germany), Hisamitsu Pharmaceutical (Japan), Rohto Pharmaceutical (US), Romsons Group of Industries (India), and Others.
Regional Analysis:
The Americas is expected to lead the market owing to increase research and development in cold pain therapy, rising demand for the products to reduce the swelling and arthritis pain. According to the Arthritis Foundation it is estimated that 78 million people may be diagnosed with arthritis in 2040. It was also estimated that currently 31 million of Americans are affected with osteoarthritis. The increasing number prevalence of arthritis with in the population may influence the cold pain therapy market.
Europe is anticipated to be the second largest cold pain therapy market during the forecast period. The increasing prevalence of non-traumatic joint disorders such as knee pain, chronic infectious arthritis and crystalline synovitis is rising the demand for cold pain therapy products. The increase in number of surgeries also support the cold pain therapy market.  According to the National Center for Biotechnology Information 2016, publication it was reported that people affected from septic arthritis (SA) ranges between 2 and 10 per 100,000 patients in the US and Western Europe. The increasing geriatric population and increasing cases of arthritis supports the market growth of cold pain therapy market.
Asia-Pacific was expected to be the fastest growing region for the global cold pain therapy market in 2017. The market is expected to witness high growth owing to the increasing geriatric population with arthritis problem and increasing injuries during sports activities, and presence of major players in cold pain therapy market. According to the MoHFW, Government of India, 2017, reported that osteoarthritis is the most common rheumatologic disease affecting the Indian population with the prevalence of 22% to 39%. The increasing prevalence of rheumatologic disease affecting the large number of populations support the cold pain therapy market.
The Middle East and Africa holds the lowest share for cold pain therapy market due to the low per capita income and availability of alternative treatment method. However, the rising demand for pain relieving products may increase the market growth in Middle East and Africa.
Posted by at No comments:

Hemorrhoids Treatment Market 2019 - Shares, Revenue, Analysis And Forecasts Till 2023

Market Scenario:
The prevalence of hemorrhoids is found particularly between the age of 45 and 65, both in men and women. However, only a small percentage of the affected population seek any form of medical treatment like medication or surgery and instead opt for relief pills purchased from pharmacies.
Hemorrhoid is a highly uncomfortable disorder which is also known as piles. The condition is so subtle yet dangerous that most people under the age of fifty are unaware of the same. Hemorrhoids are inflamed, swollen veins situated in the anal canal and causes a strong sense of irritation in the form of both pain and itchiness. Patients who suffer from the same condition seek relief from a variety of products, boasting both negatives and positives. Direct products like wipes, creams, pads, and suppositories are highly effective at offering temporary period of relief. However, it is not effective enough for permanent treatments.
According to the latest report by the team of Market Research Future (MRFR), the global hemorrhoids treatment market size is expected to grow at a decent rate of 7.1% during the forecast period of 2018 to 2023. The market growth is influenced by numerous factors like the increasing prevalence of lifestyle-based diseases, growing demand for treatment, an increasing demand for reducing infections & complications relating to hemorrhoids, and an increasing number of surgeries. The growing old-age population is also one of the key contributors to the global demand for hemorrhoids treatment. However, lack of awareness and hesitancy towards medical treatment due to the feeling of embarrassment stands out as a key constraint to the growth of the global market.
Market Segmentation
The global hemorrhoids treatment market segmentation is based in terms of route of administration, treatment type, distribution channel, and region.
By treatment type, the market segments into drugs, surgical procedures, and non-surgical procedures. The drugs segment is further segmented into NSAIDs, laxatives, and herbals. The non-surgical procedures narrows down into cryotherapy, band litigation, and sclerotherapy.
By route of administration, the market divides into oral and topical agents.
By distribution channel, the market includes hospital pharmacies, retail pharmacies, online pharmacies, and others.
Regional Analysis
The regional segmentation of the global hemorrhoids market covers four major regions globally, namely Asia Pacific, Europe, the Americas, and the Middle East & Africa.
The Americas hold the maximum share of the market as per the global standings. The dominance of the region can be attributed to the huge patient population, high expenditure in the healthcare sector, and a well-established technology. The regional market for hemorrhoids treatment is expected to continue its dominance in the forthcoming years.
Europe accounts for the second largest market globally following the Americas. The European region is segmented into key regions, namely Western and Eastern Europe. The Western European region consists of countries like the UK, Germany, and France. Factors that primarily push the market in this region are the lack of any physical exercise, sedentary lifestyle, obesity, alcoholism, poor fiber intake in diet, etc.
Asia Pacific is slated to be the fastest growing regions in hemorrhoids. The growth in this region can be attributed to factors like the increasing demand for better diagnostic devices, rapidly improving technologies, better and safe therapeutic approach, and the presence of a massive talent pool.
Competitive Landscape
The global hemorrhoids treatment market holds a number of key players like Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company, Abbott Laboratories, Boston Scientific Corporation, GlaxoSmithKline, Pfizer Inc., AstraZeneca PLC, CONMED Corporation, Taro Pharmaceuticals Inc., Astra Zeneca, Olympus Corporation, Cook Medical, Glenmark Pharmaceuticals Bayer AG, Teva Pharmaceutical Industries Ltd, and others.
13th March 2019, Organization de Scalene announced recently the launch of Cryocure. Cryocure is an affordable medical device that is used to treat piles without any need for surgery.
8th April 2019, Trifecta Pharmaceuticals, one of the leading developers, distributors, and manufacturers of specialty OTC topical creams, gels, and ointments announced today about its distribution partnership with Walmart. The move will see Mayinglong, a hemorrhoid treatment ointment, being available on the shelves of the leading departmental store.
Posted by at No comments:

Superdisintegrants Market Expects An Extensive Growth In Roi Till 2023

Market Scenario:
The Global Superdisintegrants Market is anticipted to grow at an optimistic CAGR of 7.9% during the forecast period from 2018 to 2023. Disintegrants are substances which are included in drug formula to allow proper disintegration of the capsule or tablet into easily dissolvable particles. This plays a vital function in the fast absorption of medicine which increases its efficacy. Superdisintegrants are slightly modified disintegrants which offer higher efficiency than their traditional counterparts. Observed to have valued at USD 371 Mn in 2017, the global superdisintegrants market size is poised to appreciate to reach an estimated value of USD 576.2 Mn by the end of 2023.
The pharmaceutical industry is growing at breakneck speed, becoming a significant part of the healthcare sector. This is primarily due to rising populations of both geriatric patients and pediatric patients. Superdisintegrants are helpful for treatment of patients from this demographic as these tablets are easier to swallow. The growth of these demographics is expected to drive market growth. Moreover, generic drugs are in high demand as patents have begun to run out on several popular drug brands, thus opening up the pharmaceutical industry for increased entry of competition and a rise in the manufacturing of generic drugs, thus driving superdisintegrants market demand.
Emerging markets represent significant opportunity as the healthcare sectors in these regions are growing at a swift pace. Moreover, large patient pools are in these countries are expected to increase demand for fast-acting medication. Market players are likely to establish themselves in the region in an effort to leverage the opportunities available in emerging economies.
Players Covered
Prominent market participants that have been profiled in the report include Asahi Kasei Corporation, DFE Pharma, JRS Pharma, Corel Pharma Chem, Ashland Global Holdings Inc., BASF SE, Roquette Freres, DowDuPont Inc., Merck KGaA, and Avantor Performance Materials, LLC
Market Segmentation
MRFR's analysis of the various segments in the market has been performed on the basis of type, formulation, therapeutic area, and region. Types of superdisintegrants have been segmented into synthetic superdisintegrants, natural disintegrants, and others. Among these, the synthetic superdisintegrants segment has been widely used, making it the most significant market segment. However, the natural superdisintegrants segment is growing at a truly rapid pace due to the growing demand for natural ingredients.
Formulations which include superdisintegrants have been segmented into tablets and capsules. Tablets govern a majority share of the total market, while the capsules segment is expected to grow at the highest CAGR during the review period.
Therapeutic areas where superdisintegrants are used have been segmented into gastrointestinal diseases, neurological diseases, oncology, infectious diseases, inflammatory diseases, hematological diseases, and cardiovascular diseases. Among these segments, the gastrointestinal diseases segment is at the forefront of market growth due to the demand for fast acting medicine for these types of diseases. Meanwhile, the oncology segment is growing rapidly and is expected to display the highest CAGR over the forecast period.
Regional Analysis
Led by the U.S, the Americas have captured the largest share of the global superdisintegrants market. The presence of a developed healthcare sector as well as several important market players that have and continue to influence growth and contribute to the sizeable share that this regional market possesses. The region also has a high demand for drugs for many chronic diseases where superdisintegrants are required due to the prevalence of such diseases.
The Asia Pacific superdisintegrants market is likely to grow at the highest pace due to the concentration of rapidly emerging markets in the region. China, Japan, India, and several other country-level markets have a high demand for drugs for chronic diseases. The APAC regional market has several avenues for growth that are expected to open up in the coming years. The regions rapidly growing healthcare sector and the presence of a number of contract manufacturing organizations for pharmaceuticals is likely to have a positive impact on the market.
Posted by at No comments:

Monday, 27 April 2020

Heart Tumor Market: 2020 Global Sales, Size, Share, Competitive Analysis, Upcoming Opportunities, and Forecast To 2023

Heart Tumor Market Scenario
According to the surgery and autopsy reports, primary cardiac tumors are rare with an incidence rate of about 0.3%-0.7%. Malignant primary cardiac sarcomas are usually located in the right atrium of the heart and are most commonly angiosarcomas. The malignant primary cardiac tumors are often diagnosed in young patientswho have a poor prognosis and survival rate of only 10% According to the WHO, the prevalence of melanoma skin cancers has been increasing from the past few decades. Furthermore, 132,000 melanoma skin cancers cases are reported each year across the globe.
The Global Heart Tumor Market Size is expected to grow at a CAGR of approximately 7.1% during the forecast period.
Cardiac tumors is a rare disease that are difficult to diagnose. They are divided on the basis of type into primary and secondary tumors. The prevalance of the secondary tumors is higher than the primary tumors. Majority of the primary cardiac tumors are benign in origin. The high incidences of metastatic tumors  is attributed to various types of  cancers such as lung, breast, renal cancer, lymphomas and melanomas. Clinical manifestations of these tumors generally based on  the size and location of the tumors and spread to the adjacent tissues rather than the type of the tumor itself.  Echocardiography is the major tool used for diagnosis of the tumors. Other imaging modalities include cardiac MRI, cardiac CT, and 3D echocardiography, which may offer some additional information with histological examination.
A small percentage of cardiac tumor cases are hereditary, the tumors can also be associated with another health condition, such as LAMB Syndrome, Carney Syndrome or NAME Syndrome. However, most often, the tumor develops without being associated with any health condition or presence of a family history. They result from cell overgrowth but mostly cardiac tumors results from metastatic condition, where cells from other cancerous organ such as lung and breast, soft-tissues and metastasizes to the heart.
Heart Tumor Market Key Players
Some of key the players in the Global cardiac tumor market are Tomtec Imaging Systems GmBh, Koninklijke Philips N.V., Siemens Healthineers, Circle Cardiovascular Imaging Inc., Toshiba Corporation, Shimadzu Corporation, CardioComm Solutions Inc., Integer Holdings Corporation, Pie Medical Imaging, HeartSciences, 3mensio Medical Imaging, and eMedica, S.L.

Heart Tumor Market Segmentation
The heart tumor is segmented on the basis of type, diagnosis, treatment.
On the basis of the type, the market is segmented into primary tumors and secondary tumors. The primary tumors are divided into benign and malignant. The benign tumors is further categorized into myxoma, papillary heart tumors, fibromas, rhabdomyomas, angioma, and lipomas. The malignant tumors are divided into rhabdomyosarcoma, mesenchymomas, neurosarcoma, fusiform cell tumors, malignant heart hemangioma, and lymphosarcoma. The secondary tumor is categorized into metastatic and contiguity. The metastatic secondary tumors are divided into hematogenic and lymphatic and the contiguity is sub categorized into mediastinal tumors, lung tumors and oesophageal, or cardia tumor.
On the basis of the diagnosis, the market is classified into echocardiogram, Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI), radionuclide imaging, Position Emission Tomography (PET) Scan, myocardial biopsy, cardiac catherization, and electrophysiology test.
On the basis of the treatment, the market is classified into surgery, chemotherapy, radiation therapy. Furthermore, the surgery is further categorized into open heart surgery, minimal invasive surgery, and heart transplant surgery 
International Heart Tumor Market Regional Analysis
The global heart tumor market consists of four major regions: the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominate the market owing to the rising awareness among people and increasing healthcare expenditure. The type of tumors also aids in selection of treatment procedure. For instance, in patient with heart cancers, the results of cardiac imaging could be used to see if the the tumor is spread to the adjacent tissues, which can be further used to remove the portion by performing excision surgery or pursuing treatment with medications.
Posted by at No comments:

Global Encephalomalacia Market 2020 Study and Analysis Research Report Forecast To 2023

Market Scenario
Softening or loss of brain tissue is termed as encephalomalacia and is a severe type of brain damage. Encephalomalacia disorder can also be classified into the three categories depending on their colors and the stages of damage i.e. red softening yellow softening, and white softening. The major causes of encephalomalacia are inflammation or hemorrhages that are a consequence of being afflicted by cerebral infarction, cerebral ischemia, infection, craniocerebral trauma, or another injury. Moreover, stroke is the most commonly known cause of encephalomalacia and stroke can be caused by either a head injury or a brain hemorrhage or both of them cause internal bleeding in brain. Furthermore, strokes occur due to reduced or interrupted blood supply to the brain, which is caused by blocked arteries or a burst blood vessel. Moreover, people with diabetes, blood sugar levels that become too high (hyperglycemia) or too low (hypoglycemia) which increases chances of strokes.
People who have been rescued from drowning or those who have been resuscitated after a heart attack may not awaken due to lack of oxygen to the brain. Furthermore infections such as encephalitis and meningitis cause swelling or inflammation of the brain, spinal cord or the tissues that surround the brain in severe cases of these infections can result in brain disorder.
Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods to boost to the Encephalomalacia market size. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period
Furthermore, globalization in healthcare has increased the market growth. Established market players in the developed countries leads the globalization by pushing new products and services into the developing countries and emerging economies. 
According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden, which is expected to increase further over the coming years.
However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.
The global encephalomalacia market is expected to grow at a CAGR of ~6.1% during the forecast period 2017-2023.
Key Players
Some of key the players in the market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others.
Segmentations
The global encephalomalacia market is segmented on the basis of types, diagnosis, treatment, and end user.
On the basis of the type, it is segmented into leukoencephalomalacia (encephalomalacia affecting the white matter), and polioencephalomalacia (encephalomalacia affecting the gray matter).  
On the basis of the diagnosis, it is segmented into blood test, brain scans, and others. A brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).
On the basis of the treatment, it is segmented into medical treatment, surgery, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research laboratories, and others.
Regional Analysis
The Americas dominate the global encephalomalacia market owing to well-developed technology, increasing prevalence of brain disorder, high health care spending, and increasing government support for research & development in the healthcare sector. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
Europe holds the second position in the global encephalomalacia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.     
The Asia Pacific is the fastest growing encephalomalacia market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across th`e globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.   
On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Posted by at No comments:

Spongiform Encephalopathy Market Global Research Report 2020 Analysis & Forecast to 2023

Transmissible spongiform encephalopathy (TSEs) or prion diseases are a group of invariably fatal conditions that affect central nervous system (CNS) and more specifically the brain and spinal cord. The most commonly known prion diseases in human are Fatal Familial Insomnia, Creutzfeldt - Jakob disease (CJD), Gerstmann-Straussler-Scheinker Syndrome, and Kuru, and most commonly identified animal prion diseases are Transmissible mink encephalopathy, Bovine Spongiform Encephalopathy (BSE), Scrapie, and others.
BSE (bovine spongiform encephalopathy) is one of the most common neurological disorder found in cattle that results from a transmissible agent called a prion. According to the Centers for Disease Control and Prevention, five cases of BSE are found in the U.S. and 20 in Canada in 2017.
A number of factors such as rising facilities for patients affected by encephalopathy, increasing awareness among people, increasing government assistance, and improvement in regulatory framework are propelling the growth of the global spongiform encephalopathy market.
Despite these drivers, challenges in research and development, and poor healthcare system in low and middle-income countries may hamper the growth of the market.
It is estimated that spongiform encephalopathy market size expected to grow at a healthy CAGR of 6.1% during the forecast period 2017-2023.
Key Players
Teva Pharmaceuticals, Abbvie, Adamas Pharmaceuticals, Inc., Newron Pharmaceuticals SPA, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Lonza, Merck KGaA, Thermo Fisher Scientific Inc., and others.
Regional Analysis
The Asia Pacific is the fastest growing spongiform encephalopathy market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the year 2014-15.
Europe dominates the spongiform encephalopathy market owing to the high prevalence of bovine spongiform encephalopathy in European region, support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region
The Americas hold the second position in the spongiform encephalopathy market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the U.S. was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
The Middle East & Africa owns the least share of the global spongiform encephalopathy market due to lack of technical knowledge and poor medical facilities.
Segmentation
The spongiform encephalopathy market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into in humans, in animals. The human's segment is classified into Creutzfeldt-Jakob disease, Variant Creutzfeldt-Jakob disease (vCJD), others. The others segment includes Gerstmann-Sträussler-Scheinker disease, fatal familial insomnia, and kuru (Papua New Guinea). The animals segment is classified into bovine spongiform encephalopathy (BSE), Scrapie in sheep and goats, Chronic Wasting Disease (CWD), Feline spongiform encephalopathy, others. BSE is further classified into classical BSE and atypical BSE.
On the basis of the diagnosis, the market is classified into histopathology and immunohistochemistry, immunochemical detection methods, animal bioassays, cell culture assay systems, protein misfolding cyclic amplification, conformation-dependent immunoassay, capillary electrophoresis, fluorescent correlation spectroscopy, multispectral ultraviolet fluorescence spectroscopy, and Fourier transform infrared spectroscopy. Histopathology and Immunohistochemistry are further segmented into immunohistochemical staining and electron microscopy. Immunochemical Detection Methods is further segmented into Western Blotting Test, and Enzyme-Linked Immunosorbent Assay (ELISA).
On the basis of the treatment, the market is classified into small molecules, and immunotherapies. The small molecules are further classified into pentosan polysulfate, quinacrine, amphotericin B, and others. Immunotherapies are further classified into Antibody-based immunotherapies and Cell-Based Immunotherapies. Antibody-based immunotherapies include passive immunization, active immunization, and targeting disease-specific epitopes. Cell-based immunotherapies include DC vaccines and adoptive transfer of CD4+ T-cells.
On the basis of the end-users, the market is segmented into hospital & clinics, diagnostic centers veterinary hospitals, research & academic laboratories, and others.
Posted by at No comments:

Bone Scan Market 2020 Global Growth Opportunities, Key Driving Factors, Industry Scenario and Forecast to 2023

Market Synopsis of the Global Bone Scan Market
According to the WHO, about 59% of the mortality is due to chronic diseases and almost 35 million people die of chronic diseases across the globe.
The global bone scan market is expected to grow at a CAGR of 5.7% during the forecast period.
A bone scan is a test of nuclear medicine and is mostly used to diagnose various bone diseases such as arthritis and bone cancer. It includes an injection of radioactive material and then the bone scan. Radioactive material also known as the tracer is injected into a vein. After injecting this material, the radiologist performs a bone scan. The radiologist may perform the bone scan in phases depending upon the condition to be diagnosed such as the presence of bone disease or cancer.
Rising prevalence of bone disease, increasing demand for imaging devices such as MRI, CT scan, SPECT scan, and increasing health care services are accelerating the growth of the market. Furthermore, the increasing expenditure on medical devices influences the market growth. Technological advancements in radiology devices affecting the market growth. However, the efficiency of bone scan may hinder the market growth over the forecast period. Additionally, the bone scan may determine the inaccurate cause of the abnormality.
Key Players in the Global Bone Scan Market   
  • Siemens (U.S.)
  • Hitachi, Ltd. (Japan)
  • Carestream Health, Inc. (U.S.)
  • Samsung Electronics Co., Ltd. (South Korea)
  • Toshiba Corporation. (Japan)
  • Koninklijke Philips N.V. (Netherlands)
  • General Electric Company (U.S.)
Segments of the Global Bone Scan Market
The global bone scan market is segmented on the basis of product, indication, device, and end user.
On the basis of the product, the market is segmented into radiopharmaceuticals and imaging devices. The imaging devices are further segmented into Magnetic Resonance Imaging (MRI), X-ray, Computed Tomography (CT), Single-Photon Emission Computerized Tomography (SPECT), and others.
On the basis of the application, the market is segmented into fractures, arthritis, Paget's disease of bone, cancer originating in bone, and others.
On the basis of the end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Regional Analysis
The Americas lead the global bone scan market size owing to the rising prevalence of bone disorders in the U.S. Furthermore, increasing demand for diagnostic services in various also influences the market growth. In North America, the U.S. is the largest market followed by Canada. Increasing penetration of orthopedic specialty hospitals and healthcare insurance is adding fuel to the market growth. Furthermore, the concentration of key players in the market along with the availability of various technologically advanced devices is boosting the market growth in the U.S.
Europe is the second largest bone scan market across the globe. The market is accelerated by the extensive use of diagnostic devices for diagnosis of various chronic diseases such as arthritis, diabetes, obesity and others. Furthermore, extensive research and development (R&D) activities carried out by clinical research and academic institutes stimulate the growth of the market. Germany and France contribute to the growth of the market owing to increasing expenditure on R&D and extensive demand for diagnostic devcies.
The Asia Pacific market is expected to grow at the fastest pace due to the high prevalence of chronic disease such as rheumatoid arthritis, osteoarthritis, obesity, diabetes, and other. Additionally, increasing number of bone injuries such as bone fractures boost the growth of the market.  To add further, increasing number of skilled professionals along with increasing awareness about the bone diseases and importance of imaging tests in the diagnosis of bone diseases, and injuries. In Asia Pacific, India and China are holding the largest market share followed by Japan. Increasing expenditure on healthcare and improving healthcare infrastructure in various developing regions of Asia Pacific region are affecting the market growth, positively.
Posted by at No comments:
Subscribe to: Posts (Atom)